Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$22.4M | -$28.6M | -$74.2M | -$78.9M | -$91.8M | -$111M | -$143M | -$143M |
| Net income | -$21.4M | -$26.9M | -$73.7M | -$78.7M | -$89.1M | -$101M | -$128M | -$129M |
| EPS (diluted) | -$12.32 | -$14.15 | -$3.36 | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.7M | -$23.5M | -$45.3M | -$59.5M | -$75.1M | -$85.7M | -$113M | -$111M |
| Capital expenditures | $525K | $768K | $667K | $939K | $2.08M | $849K | $1.19M | $712K |
| Free cash flow | -$21.2M | -$24.3M | -$45.9M | -$60.5M | -$77.2M | -$86.5M | -$114M | -$112M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $42.6M | $89.2M | $78.4M | $226M | $66.8M | $23.4M | $59.4M | $45.7M |
| Total assets | — | $94.1M | $299M | $299M | $247M | $252M | $274M | $409M |
| Total liabilities | — | $6.12M | $9.22M | $25.7M | $24.8M | $27.9M | $31.0M | $24.5M |
| Long-term debt | — | — | — | $10.5M | — | — | — | — |
| Shareholders' equity | -$64.4M | -$90.1M | $290M | $273M | $222M | $224M | $243M | $384M |
| Retained earnings | — | -$92.7M | -$166M | -$245M | -$334M | -$435M | -$563M | -$692M |
| Shares (wtd avg diluted) | — | 1.98M | 36.7M | 38.0M | 39.7M | 51.5M | 69.7M | 87.8M |
Every figure is extracted from Oric Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.